1. Scrip
  2. >>Conferences
  3. >>ASCO

Merck's Keytruda Doubled PFS In Some Colorectal Cancer Patients In ASCO Late-Breaker

 
• By Jessica Merrill

Pembrolizumab should be considered the new standard of care as first-line therapy in patients with microsatellite instability high (MSI-H) metastatic colorectal cancer, KEYNOTE-177 investigator André said.

Three green arrows hitting the center of a black target and 3 darts out of the objective. Business strategy or competitive advantage concept. Space for text on the left side.
Merck's Keytruda doubled PFS in some colorectal cancer patients • Source: Shutterstock

Merck & Co. Inc.'s Phase III KEYNOTE-177 trial studying its PD-1 therapy Keytruda (pembrolizumab) versus chemotherapy showed the cancer immunotherapy should be the new standard of care for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer, lead investigator Thierry André, Sorbonne Université, told a press briefing ahead of the opening of the American Society of Clinical Oncology (ASCO) virtual meeting.

KEYNOTE-177 – one of seven late-breaker abstracts featured by ASCO – is the first Phase III trial to study Keytruda as a monotherapy versus standard of care (chemotherapy plus bevacizumab or cetixumab) as first-line therapy in MSI-H metastatic colorectal cancer

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

TIL The CARs Come Home: How Cell Therapy’s Solid Tumor Future Is Shaping Up

 
• By Alaric DeArment

Iovance’s Amtagvi won FDA accelerated approval in February, and Adaptimmune’s afami-cel may not be far behind, but cell therapies for solid tumors come with some extra challenges.

Anti-TROP2 ADCs Lung Cancer Futures Likely Lie In Earlier-Stage Disease

 
• By Alaric DeArment

The discussant at ASCO’s NSCLC session said the field would need to “manage expectations” as the drugs do not appear to beat chemotherapy in all-comers. 

ASCO 2024 Wrap-Up Podcast

 
• By Alaric DeArment

Scrip reporter Alaric DeArment is joined by the Datamonitor Healthcare oncology analysts to review key highlights from the recent American Society of Clinical Oncology annual meeting.   

China Biotech Podcast: BIOSECURE Act Updates ASCO Highlights

 
• By Brian Yang and Dexter Jie Yan

US-based Citeline writer Sarah Karlin-Smith joins Brian Yang and Dexter Yan in China to discuss the US BIOSECURE Act and the recent BIO meeting in San Diego, while Dexter Yan discusses China-related ASCO highlights, in this mixed Chinese- and English-language episode.

More from Conferences

Balance And Focus Suggested For Globalizing Chinese Firms Amid Ongoing Uncertainties

 
• By Xu Hu

Finding a balance between out-licensing, refocusing on internal strengths and addressing unmet needs were identified at a recent Shanghai conference as some of the key strategies for Chinese biopharma firms looking to truly globalize.

Cash-Strapped Chinese Biotechs A Growing Draw For Western Pharma Partnering

 
• By Alaric DeArment

Nauman Shah, head of business development for J&J Innovation, sat down at the BIO CEO & Investor Conference to talk about his trip to China and the state of the biotech scene there.

Lexicon Has A Lot Riding On LX9211 Phase IIb Readout In Pain

 
• By Jessica Merrill

CEO Mike Exton talked to Scrip about moving the company forward after a disappointingly disruptive 2024.